N-propargyl-1-aminoindan mesylate

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2005
01219982005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Neuronal death in Parkinson's disease (PD) may originate from the reciprocal interactions of a restricted number of conditions… (More)
Is this relevant?
2003
2003
The anti Parkinson drug, rasagiline [R-(+)-N-propargyl-1-aminoindan], an inhibitor of type B monoamine oxidase, has been shown to… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2002
2002
Clinical trials for treatment of Parkinson's disease suggest that (−)deprenyl (selegiline), an inhibitor of type B monoamine… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2002
Review
2002
In Parkinson's disease (PD), therapies to delay or suppress the progression of cell death in nigrostriatal dopamine neurons have… (More)
Is this relevant?
2000
2000
A potent inhibitor of type B monoamine oxidase, (-)deprenyl, is known to protect or rescue dying neurons, independent of… (More)
Is this relevant?
1998
1998
Striatal extracellular fluid concentrations of dopamine and metabolites in response to direct striatal administration of two L… (More)
Is this relevant?
1998
1998
(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase… (More)
Is this relevant?